Alzheon Announces Peer-Reviewed Scientific Publication of Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in APOE4/4 Homozygou…

Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of investigational therapies and ...
Healio

Donanemab improves outcomes in early-stage Alzheimer’s disease up to 3 years

Please provide your email address to receive an email when new articles are posted on . Earlier initiation of donanemab reduced the risk of disease progression on the Clinical Dementia Rating-Global ...

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China

In January 2024, LEQEMBI was approved for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as ...
Hosted on MSN

For Your Patients: Navigating Treatment Options in Early Stage Alzheimer’s Disease

With early diagnosis of Alzheimer's disease comes the possibility of treatment to not only help manage symptoms but also slow progression to a more advanced stage. Your doctor may prescribe a type of ...

FDA greenlights Alzheimer’s blood test to rule out disease

The Food and Drug Administration has given approval for a blood test that will rule out if someone has Alzheimer’s disease ...
Healio

Adherence to lifestyle intervention linked to better outcomes in early-stage Alzheimer’s

Please provide your email address to receive an email when new articles are posted on . Active intervention correlated to better cerebral blood flow in areas of memory, executive function and language ...

FDA Clears New Blood Test to Help Rule Out Alzheimer’s Disease

The Elecsys pTau181 blood test has been cleared to help rule out Alzheimer’s disease. The test correctly identified people ...